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Abstract
Currently, most of the basic mechanisms governing tumor-immune system interactions, in combination
with modulations of tumor-associated vasculature, are far from being completely understood. Here, we
propose a mathematical model of vascularized tumor growth, where the main novelty is the modeling
of the interplay between functional tumor vasculature and effector cell recruitment dynamics. Parame-
ters are calibrated on the basis of different in vivo immunocompromised Rag1−/− and wild-type (WT)
BALB/c murine tumor growth experiments. The model analysis supports that tumor vasculature nor-
malization can be a plausible and effective strategy to treat cancer when combined with appropriate
immuno-stimulations. We find that improved levels of functional tumor vasculature, potentially medi-
ated by normalization or stress alleviation strategies, can provide beneficial outcomes in terms of tumor
burden reduction and growth control. Normalization of tumor blood vessels opens a therapeutic win-
dow of opportunity to augment the antitumor immune responses, as well as to reduce the intratumoral
immunosuppression and induced-hypoxia due to vascular abnormalities. The potential success of normal-
izing tumor-associated vasculature closely depends on the effector cell recruitment dynamics and tumor
sizes. Furthermore, an arbitrary increase of initial effector cell concentration does not necessarily imply
a better tumor control. We evidence the existence of an optimal concentration range of effector cells for
tumor shrinkage. Based on these findings, we suggest a theory-driven therapeutic proposal that optimally
combines immuno- and vaso-modulatory interventions.
Keywords: tumor-immune system interactions, murine tumor growth experiments, vascular normaliza-
tion, immuno-modulatory interventions, mathematical modeling.
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2Major Findings
We propose a tumor-effector cell recruitment model, where the main novelty is the low dimensional mod-
eling of the complex interplay between functional tumor-associated vasculature and effector cell recruit-
ment dynamics. Improved tumor vascularization, either via normalization or due to a microenvironmental
stress alleviation strategy, is predicted to open a therapeutic window of opportunity in the treatment of
cancer. Normalizing tumor vasculature as a potential therapeutic target closely depends on the immune
recruitment dynamics and tumor sizes. Moreover, arbitrary low or high initial concentrations of effector
cells can be detrimental to clinical outcomes, which evidences the existence of an optimal concentration
range of effector cells that is crucial to obtain tumor control.
Introduction
Suppression of tumor angiogenesis has been recognized for more than four decades as a therapeutic
target to treat solid tumors, as well as a complementary method of cancer prevention [1–3]. Tradi-
tionally, antiangiogenesis strategies attempt to inhibit new blood vessels formation within the tumor
microenvironment, while at the same time reducing as much as possible the functionality of existing
tumor-associated vasculature. A wide array of drugs to inhibit tumor angiogenesis, such as bevacizumab
(Avastin, Genentech/Roche), a ligand-trapping monoclonal antibody against VEGF, and the inhibitors
of multiple protein kinase targets, sorafenib (Nexavar, Bayer) and sunitinib (Sutent, Pfizer), has been
successfully used in the clinic to treat solid tumors [4]. However, different preclinical and clinical trials
reveal that angiogenesis inhibitors alone have limited efficacy and only offer a modest survival benefit
in a reduced cancer patient population [5, 6]. The clinical benefits of antiangiogenesis treatments are
not only limited in terms of tumor shrinkage, vasculature destruction and patient survival, but also are
restricted by transient effects, insufficient efficacy or development of treatment resistance [2, 7, 8]. There
are increasing evidences that the antitumor activity of most antiangiogenic drugs only became clinically
significant in combination with conventional therapeutic modalities such as radiotherapy, chemotherapy
or immunotherapy [9–11].
Tumor-associated vasculature exhibits opposing effects on tumor growth, invasion and progression
[2, 7, 8]. On the one hand, blood vessels are required for delivery of oxygen and nutrients to the tumor,
which promotes its growth, and they provide malignant cells with a way to spread, invade and metastasize
into other healthy areas of the body [7,12–14]. On the other hand, blood vessels reoxygenate the tumor,
which increases its radiosensitivity, and improve delivery of cytotoxic drugs to the tumor bulk as well as
infiltration of immune cells into the tumor parenchyma [7, 11, 15, 16]. In view of these opposing effects,
the right treatment of a cancer patient relies on a mechanistic understanding and quantitative analysis of
the cancer-mediated processes involved. This demands for a mathematical model of tumor growth that
considers the interplay between functional tumor vasculature and immune cell recruitment dynamics.
There are several mathematical models of tumor growth, where some forms of the immune system
dynamics were included [17–21]. Different immuno-oncology studies reveal that tumors can survive
in a microscopic and undetectable dormant state [19, 20, 22], as inferred from clinical data [23]. This
equilibrium can be disrupted by sudden events affecting the immune system. Indeed, the neoplasm
develops several strategies to circumvent the action of the immune system [24,25], which could result in
tumor evasion and regrowth [25]. Sustained oscillations by the immune system have been observed both in
its healthy state and pathological situations [22,26,27]. An elegant mathematical model of the dynamics of
immunogenic tumors revealed that tumor-immune system interactions can produce cyclic behaviors [28].
In fact, the presence of an immune component in mathematical models has been described to be crucial
for reproducing observed phenomena such as tumor dormancy and oscillatory growth [22, 28–30]. This
was complemented by a detailed discussion of the importance of including an immune component in
tumor growth models, see [29] and references therein, and was subject to several reviews [17, 31–35].
3Some of the models mainly focus on spatial aspects described either by partial differential equations or
by cellular automatas or by realistic mechanical cell interactions [31,33,36,37], while others focus on non-
spatial dynamics described by ordinary differential equations [34, 38]. Mathematical modeling provides
a valuable theoretical framework to perform in silico experiments, as well as to verify assumptions and
suggests modifications of existing theories. Despite years of research, and the vast amount of reported
mathematical models, there are still many unanswered questions regarding the critical components of
the tumor microenvironment and their role in the associated immuno-oncological mechanisms. However,
models were rather successful in optimizing therapeutical protocols based on quantitative incorporation
of experimental or patient data [29,39–45]. The work presented here, follows this latter approach.
We intend to generate novel mechanistic insights not only on the interactions between the immune
system and growing tumors, but also on the role of the functional tumor-associated vasculature. The
main goal is to use the better understanding to suggest optimized treatment strategies. For that purpose,
we combined a mathematical model of radially symmetric tumor growth [46–49] with an immune cell
model [28] to propose a tumor-effector cell recruitment model. The main novelty is that the impact of
functional tumor vasculature on the effector cell recruitment dynamics is included. Previous models of
tumor-immune system interactions did not directly incorporate the effect of tumor vascularization, and
thus underestimated the relevance of this crucial mechanism for tumor growth and treatment outcomes.
Based on well-supported biological assumptions, we derive that tumor vasculature normalization opens
a therapeutic window of opportunity for tumor growth control. The potential benefit of a vascular
normalization strategy relies on a specific immune recruitment dynamic into the tumor microenvironment.
We also find that an unlimited increase on the initial effector cell concentration does not necessarily
imply a better tumor control. The proposed model is capable of providing a more complete view of
vascularization effects on the immune responses to tumor growth, and it is therefore suited for analysis
and prediction of treatment strategies.
Quick Guide to Model Equations and Assumptions
A radial tumor growth model
We consider a mathematical model of radial tumor growth which was originally proposed in [46], see
also [48, 49]. The tumor is assumed as an incompressible fluid flowing through a porous medium, where
tissue elasticity is simplified. The tumor-host interface is considered to be sharp, and cell-to-cell adhesive
forces are modelled as a surface tension at that interface. The tumor expands as a mass whose growth is
governed by a balance between cell birth (mitosis) and death (apoptosis and necrosis). The mitotic rate
within the tumor is assumed to be linearly-dependent on the nutrient concentration (oxygen, glucose,
etc.) and is characterized by its maximal value λM at the tumor-host interface. The death rate λA
is considered uniform within the tumor and assumed constant in time. The concentration of nutrients
obeys a reaction-diffusion equation in the tumor volume, where nutrients are supplied from the functional
tumor vasculature and consumed by the tumor cells at a uniform consumption rate (see the derivation
of the mathematical model provided in the Supplementary Material for further details).
The resulting dimensional mathematical model for the tumor radius R(t) dynamics, under the as-
sumption of radial symmetry, is given by
dR
dt
=
1
3
(λMB − λA)R+ λM (1−B)LD
(
1
tanh(R/LD)
− LD
R
)
. (1)
This model given by Eq. (1) can be interpreted as the temporal evolution of the average tumor radius,
since radial symmetric growth is not a realistic behaviour. Notice that, multiplication of Eq. (1) by R2
describes the time evolution of the tumor volume (see the Supplementary Material for more details). The
non-negative and dimensionless parameter B represents the net effect of tumor-associated vasculature on
4the tumor radius dynamic. Moreover, LD is an intrinsic scale representing the average length of nutrient
gradient, i.e. supply, diffusion and consumption.
A tumor-effector cell recruitment model considering the impact of functional
tumor-associated vasculature
The proposed tumor-effector cell recruitment model is a combination of the radial tumor growth model
given by Eq. (1) and an effector cell model initially introduced in [28], see also [20, 50]. In addition, we
consider the impact of functional tumor vasculature on the tumor growth and immune response dynamics.
The system variables are the average tumor radius R(t) and effector cell concentration E(t) in the tumor
vicinity. The model is formulated as a system of ordinary differential equations (ODEs) given by
dR
dt
=
1
3
(λMB − λA)R+ λM (1−B)LD
(
1
tanh(R/LD)
− LD
R
)
− cERf(R,α), (2)
dE
dt
= r
R3
K +R3
E − (d1R3f(R,α) + d0)E + σ, (3)
where the time coordinate t on the system variables has been omitted for notational simplicity. The non-
dimensionalized version of the model is provided in the Supplementary Material. In words, the Eqs. (2)
and (3) can be respectively read as follows
{change of tumor radius} = {net vascular tumor growth} + {avascular tumor growth} - {death of tumor
cells due to effectors},
{change of effector cell concentration} = {immune recruitment} - {inactivation + death of effector cells}
+ {background rate of immune effector recruitment}.
The expression f(R,α) = R
α−1
Rα−1+1 ∈ [0, 1], for α ∈ [0, 1), is a phenomenological scaling function that
models the infiltration of effector cells into the tumor bulk through the existing functional tumor vascu-
lature. This function modulates the terms related to tumor-effector cell interactions, such as killing of
tumor cells due to effectors and inactivation of effectors due to their antitumor activity. As a particular
case, we assume that α = B, where 0 ≤ B ≤ 1 represents the net effect of functional levels of the
tumor-associated vasculature. In the limit of avascular tumor growth B = 0, such tumor-effector cell
interactions take place only at the tumor surface. At the other extreme, for B = 1 effector cells can
potentially interact with any cancer cell within the tumor bulk. Notice that such scaling functions have
been also considered in the classical von Bertalanffy approach and more recently in allometric models [51].
Alternatively, we can view the encountering of effector and tumor cells mediated by fractal vasculature
as a percolation process within the tumor mass. In this context, the term f(R,α) scales the average
effector-tumor cell encountering rate in a vascularized tumor. In particular, the scaling term should be
proportional to the corresponding percolation cluster mass of system size R and fractal dimension 3α,
where the latter depends on the structure of tumor-associated vasculature [52].
Model assumptions
1. The temporal evolution of the average tumor radius is considered, where invasive and diffusive
tumor mechanisms are not taken into account.
2. The death rate λA of tumor cells reflects the lump effect of apoptotic and necrotic processes.
3. Innate immunity or base immune surveillance is represented as a minimum presence of active effector
cells at any time, even in the absence of cancer cells.
54. Effector cells are recruited depending on the concentration of tumor cells according to Michaelis-
Menten dynamics.
5. The efficacy of immune killing depends on the ability of effector cells to penetrate the tumor bulk via
the functional tumor-associated vasculature [10, 11]. With improved vascularization, the effectors
kill tumor cells not only on the surface of the tumor, but also further inside.
6. Effector cells die with a constant rate and get inactivated in dependence on their antitumor activity.
Materials and Methods
Experimental data of tumor growth in mice
We now describe the murine experiments of in vivo tumor growth considered. BALB/c mice were pur-
chased (Janvier, France). Rag1−/− mice were purchased from The Jackson Laboratory (C.129S7(B6)-
Rag1tm1Mom/J). Igα−/− mice were obtained from Michael Reth, Freiburg, Germany (Cd79atm2Pld).
All recombinant mice were bred at the HZI and all experiments were performed with female, 8-12 weeks
old mice if not stated differently and under approval of LAVES (Niedersa¨chsisches Landesamt fu¨r Ver-
braucherschutz und Lebensmittelsicherheit); Permission: 33.9-42502-04-12/0173. Unlike wild-type (WT)
BALB/c mice, immunocompromised Rag1−/− mice cannot produce functional T- and B-cells, i.e. have
no adaptive immune responses.
CT26 (ATCC CRL-2638) cells were cultured in IMDM supplemented with 10% FCS, 100 U/ml peni-
cillin and 100 µg/ml streptomycin, 50 µM 2-mercaptoethanol, 2 µM L-glutamine and maintained at 37 ◦C
and 5% CO2. The F1A11 (H-2
d) cell line is a murine fibrosarcoma that expresses β-galactosidase (β-gal)
and was obtained by transduction of spontaneously transformed BALB/c fibroblast cell line F1 with the
LBSN retroviral vector [53]. Tumors CT26 and F1A11 were set by injecting 5× 105 cells in 100 µl PBS
subcutaneously (s.c.). Growth was monitored by caliper and the mean tumor radius evolution between
days 4 to 9 was observed. Volume was calculated as V = 4/3pi(hw2)/8, where h = height and w = width.
Estimation of model parameters
The experimental data corresponding to immunocompromised Rag1−/− and wild-type (WT) BALB/c
mice are analyzed in two different phases. In the first phase (days 0 to 4) exponential avascular tumor
growth is assumed [54]. Using the tumor radius at those early times of growth, the net proliferation
rate of cancer cells is estimated. The tumor radius evolutions in the second phase of growth (days 4
to 9) are then used to determine the remaining model parameter values. Because of uncertainties due
to the finite number of observations, consisting in 15 and 20 individual experimental trials respectively,
we have implemented a bootstrapping procedure for each dataset considered. The goal was to obtain
reliable estimates of the summary statistics, where a resampling procedure has been performed. A set
of bootstrap samples is artificially generated and represents the natural variations in the experimental
datasets [55]. More precisely, we have considered non-parametric bootstrap samples, i.e. samples that
have been generated from the original experimental datasets by drawing with replacements. The default
size managed, also called cloud size, has been 100 000 bootstrap samples per dataset, where the resulting
mean and standard deviation of such samples have been considered for parameter calibration. Another
crucial factor to obtain precise model fitting is to consider different initial parameter values. Consequently,
we started the fitting procedure from a large number of different random initial conditions, as well as
by randomly perturbing the model parameter set to be estimated. Then, the solution with the lowest
residual variance was selected, which thus provides the best fit.
6Early exponential tumor growth phase (days 0 to 4)
For a precise understanding of the early tumor growth phase predicted by our mathematical model,
we work under the small tumor radius assumption and Taylor expand the r.h.s. of Eq. (1) accordingly.
Keeping terms up to the first nonlinear term, we obtain the following approximation
dR
dt
' 1
3
(λM − λA)R− λM (1−B)
45L2D
R3. (4)
The very early tumor growth phase, dictated by the first term of this approximation, is always of
exponential nature and does not depend on the parameter B, i.e. the tumor vascularization effects, as
reported also in [48,49,54]. Therefore, this initial phase depends exclusively on the net proliferation rate of
cancer cells, λp = (λM −λA). Considering the initial tumor radius in the immunocompromised Rag1−/−
mice experiments of 0.40 mm, which corresponds to a tumor spheroid of 5× 105 cells of about 10 µm in
diameter, and the tumor radius at day 4 of 2.0 mm, see Fig. 1(A), we find that λp ≈ 1.20±0.1 day−1. This
value is in agreement with previous estimates of growth rate (early stages) for murine CT26 spheroids [56].
Later, the initial exponential tumor growth gets affected by tumor-associated vascularization, which starts
playing a significant role when the two terms of the r.h.s. of Eq. (4) have similar orders of magnitude.
This occurs around a critical tumor radius RB derived from the condition
1
3
(λM − λA)RB ≈ λM (1−B)
45L2D
R3B . (5)
Since (λM − λA) = λp > 0 is necessary for the initial tumor growth, Eq. (5) requires 0 ≤ B < 1,
where B = 0 represents an avascular tumor and B → 1 a fully vascularized tumor. This yields
RB ≈ LD
√
15(λM − λA)
λM (1−B) . (6)
Eq. (6) provides an estimate of the tumor size at which nonlinearities, involving the vascularization
mechanisms, start significantly influencing the initial exponential tumor growth. The effect of the non-
linear terms is to saturate the growth, i.e. dR/dt = 0, when the tumor radius reaches RB . Since only
exponential growth is observed for small tumor radii, angiogenesis should be activated before the critical
tumor radius is reached and suggests that RB is an upper bound for the initiation of angiogenic processes.
The value of RB can be predicted provided the values of the parameters in Eq. (6) are known. Assuming
time-invariant values of the characteristic mitotic λM and death λA rates of cancer cells, and the relation
λp ≈ 1.20± 0.1 day−1 together with the physiological plausible value λM = 1/18h ≈ 1.34 day−1 for the
mouse colon carcinoma cell line (or CT26 murine tumor cells) [56,57], yields λA ≈ 0.14± 0.1 day−1. The
parameters B and LD, i.e. the functional tumor vasculature and intrinsic scale representing the average
length of nutrient gradient, remain to be determined, which are estimated from the growth phase ranging
between days 4 to 9.
Linear tumor growth phase (days 4 to 9)
From the experimental data corresponding to immunocompromised Rag1−/− and (WT) BALB/c mice
at the stages of growth ranging between days 4 to 9, we observe an approximately linear evolution of the
tumor radius, see Fig. 1. This observation is consistent with the long-term behavior of growth, where
linear radial evolution is prominent as reported in [54]. In Eqs. (2)-(3) this assumption is equivalent to
assigning B = λA/λM . In particular, linear radial tumor growth in immunocompromised Rag1
−/− mice
requires c = 0 in Eq. (2), because Rag1−/− mice have no adaptive anticancer immune responses. Thus,
the first and last terms on the r.h.s. of Eq. (2) vanish and allows to determine LD ≈ 0.29±0.02 mm. This
value is consistent with the well-known characteristic nutrient diffusion length that ranges between 0.2 mm
7and 0.3 mm [58,59]. In Fig. 1(A) the linear fitting results for the Rag1−/− mice dataset are represented.
The estimated parameter values allow for the calculation of RB ≈ 1.12± 0.08 mm > LD from Eq. (6) for
a tumor in the early phase of growth which begins to be influenced by the tumor-associated vasculature.
The following parameter values are taken from [20,28,50,60,61]: d0 = 0.37 day
−1, d1 = 0.01 mm−3 day−1,
K = 2.72 mm3 and σ = 0.13× 105 cells day−1.
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Figure 1: Linear fitting of the tumor radius evolution from murine experimental data. (A)
Tumor growth in immunocompromised Rag1−/− and (B) wild-type (WT) BALB/c mice at different time
points are shown together with the linear fitting results of the model. The ranges of experimental data
and standard deviations of the bootstrap samples are also shown.
Radial tumor growth can be also assumed linear for the (WT) BALB/c mice dataset, see Fig. 1(B),
which infers dR/dt = VL ≈ 0.29± 0.05 mm/day constant in the time interval between days 4 to 9, and in
agreement with growth velocity measured previously for murine CT26 tumors [62]. Then, for R  LD,
Eq. (2) becomes
1
3
(λMB − λA)R+ λM (1−B)LD − cERB = VL, (7)
where
(
1
tanh(R/LD)
− LDR
)
≈ 1, and for 0 ≤ B ≤ 1 it follows that RB
R(B−1)+1 → RB since R(B−1)  1.
Considering that R(t) = VL(t − t0) + R0, Eq. (7) provides the following evolution of the effector cell
concentration E(t) required for linear radial tumor growth
E(t) =
−VL + 13 (λMB − λA)R(t) + λM (1−B)LD
cR(t)B
. (8)
The above formula allows for the exact quantification of the initial concentration of effector cells E0,
as well as for the reduction of the number of free model parameters that enter in the fitting procedure,
since the net proliferation λp and death λA rates of cancer cells, as well as LD have been estimated from
the experimental data of immunocompromised Rag1−/− mice tumor growth. Accordingly, only three free
model parameters are left in Eqs. (2)-(3), i.e. functional tumor vasculature B, immune cell recruitment
rate r and death rate of tumor cells due to effectors c, which are estimated from the (WT) BALB/c mice
experiments imposing the expression (8) during parameter calibration. Considering variations of the
initial conditions, and randomly perturbing the parameter set to be estimated, the resulting parameter
values are provided in Tab. 1. In Fig. 1(B) the linear fitting results for the experimental data of tumor
growth in (WT) BALB/c mice are represented.
8Parameters Values Sources
c 0.03 ± 0.002 cells−1 day−1 estimated
r 0.4 ± 0.01 day−1 estimated
K 2.72 mm3 [20, 28,50,61]
d1 0.01 mm
−3 day−1 [20, 28,50,61]
d0 0.37 day
−1 [20, 28,60,61]
σ 0.13× 105 cells day−1 [20, 28,50,61]
λM 1.34 day
−1 [56, 57]
λA 0.14 ± 0.1 day−1 estimated
LD 0.29 ± 0.02 mm estimated
B 0.18 ± 0.01 estimated
E0 3.28± 1.07× 105 cells estimated
Table 1: Model parameters. Parameter values not found in the literature were estimated from in
vivo experimental data of tumor growth in immunocompromised Rag1−/− and wild-type (WT) BALB/c
mice.
Results
The dual effect of functional tumor-associated vasculature
The proposed mathematical model given by Eqs. (2)-(3) is used to investigate the effect of functional
vasculature on the gross tumor growth. Tumor-associated vascularization enhances the supply of oxygen
and nutrients, and therefore favours tumor growth and progression [12, 14]. At the same time blood
vessels facilitate the infiltration of effector cells into the tumor bulk, which potentially exterminate cancer
cells [15, 16]. These opposing effects of tumor vascularization suggest the existence of an optimal tumor
growth control, such that a quantitative modulation of functional vasculature can be considered as a
suitable therapeutic target against cancer.
In order to gain insights into the impact of functional vasculature on the short-term tumor evolution,
we vary the model parameter B in Eq. (2). The radial growth rate dR/dt, which indicates whether the
tumor radius grows (positive), decays (negative) or remains stable (zero), is monitored. Starting from
different initial concentrations of effector cells E0, Fig. 2 shows the rate of tumor growth in dependence
on the functional levels of vascularization B and initial tumor sizes R0. Above a specific threshold
concentration of effector cells, a degree of vascularization exists that maximizes tumor growth. Moreover,
above this threshold increasing vascular functionality reduces the tumor growth rate, since it allows a
high number of effector cells to penetrate into the tumor parenchyma, see diagrams for E0 ≥ 20×105 cells
in Fig. 2. Tumor shrinkage dR/dt < 0 is possible for very low functional vascularization and large tumor
radii, irrespective of the number of effector cells in the tumor vicinity. However, for small tumors and
low initial concentrations of effector cells, reduction in the tumor burden cannot be obtained for deficient
vascularization. Moreover, there exist critical E0 values at which tumor shrinkage becomes also possible
for well-vascularized tumors irrespective of their sizes, see diagram for E0 = 30× 105 cells in Fig. 2.
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Figure 2: Short-term growth rate dependence on tumor size R0 and functional vascularization
B. The radial tumor growth rate (dR/dt) is plotted against initial tumor radius R0 and functional levels
of tumor-associated vasculature B for different initial concentrations of effector cells E0. Remaining
parameters in Eq. (2) are as in Tab. 1.
A more systematic investigation of the dependence of long-term model dynamics given by Eqs. (2)-(3)
on the set of initial conditions (E0, R0) is conducted through a tumor-immune phase portrait analysis,
see Fig. 3. For functional vascular levels of B = 0.50, long-term tumor control is possible, in the sense
of damped oscillations, for all values of R0 considered, see Fig. 3(A). Tumor dormancy is described by
decaying oscillations converging to a steady-state, that once obtained is maintained for a long period of
time. However, at larger values of R0 the amplitude of the oscillations in E(t) and R(t) increases and
reaches uncontrolled growth above a threshold for R0 which determines the tumor fate. For a higher
tumor-associated vascularization, e.g. B = 0.70, long-term tumor control cannot be achieved for any set
of values of the model parameters considered, see Fig. 3(B). In contrast, for well-vascularized tumors,
e.g. B = 0.95, a window of opportunity for tumor control is predicted, see Fig. 3(C). As far as R0 stays
below a threshold value, tumor evolution can be controlled. At high and low vascularization levels, tumor
eradication is not possible for sufficiently large tumors, revealing the relation between tumor sizes and the
potential therapeutic benefit of targeting the tumor vascular network. The bifurcation analysis on model
parameters B and r, i.e. the functional tumor vasculature and immune recruitment rate, is provided in
the Supplementary Material for further details.
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Figure 3: Tumor-immune phase portrait diagrams and long-term characteristic dynamics.
(Left) Phase portrait diagrams from top to bottom representing the tumor radius R and concentration
of effector cells E time evolutions for different sets of initial conditions (colored curves) and levels of
functional tumor vascularization B. The nullclines, i.e. zero-growth isoclines, of the dynamical system
(black lines) are also represented. Each arrow provides information about the short-term (local) evolution
of the corresponding initial conditions. (Right) Panels showing the corresponding time evolution of R
(red lines) and E (blue lines) for E0 = 20 × 105 cells and different values of the initial tumor radius R0
for each value of B considered in the corresponding phase portrait diagrams on the left. The immune
recruitment rate was r = 0.59 day−1 and remaining parameters are as in Tab. 1.
Critical radius and control range of effector cell concentration determine tu-
mor fate
Fig. 3 reveals information about the existence of different dynamical regimes of the tumor-effector cell
recruitment system described by Eqs. (2)-(3) for the set of parameter values considered. Based on the
analysis of the critical fixed points and their positions in the phase space (see the phase space and critical
fixed points analysis provided in the Supplementary Material), we obtain that a spiral and a saddle point
are present. At the spiral point the tumor radius oscillates around a small tumor size, i.e. a dormancy-
associated equilibrium point. This implies a concentration range of effector cells that keep tumor under
control for a period of time that depends on the point stability. Moreover, there exists a critical tumor
radius RS , which coincides with the saddle point, that for tumors of equal or larger sizes always grow
uncontrollably and the immune system is completely suppressed. However, below this threshold tumors
are always controlled, or at least for some period of time in a transient dormant state, provided the
11
immune responses are in a specific range. The questions that arise are to (i) analytically evaluate the
critical tumor size RS that for R0 ≥ RS implies uncontrollable growth and (ii) estimate the range of
initial effector cell concentration E0 that allows for long-term tumor control.
Critical radius for tumor dormancy
These results evidence that the saddle point position in the phase space separates uncontrolled tumor
growth and immune-induced dormant states, as well as delineates the potential and limits of therapeutic
benefits of immuno- and vaso-modulatory interventions. For large well-vascularized tumors, we derive an
analytical expression that approximates the critical tumor radius RS corresponding to an upper bound
estimation of the saddle point (see the estimation of the critical radius for tumor dormancy provided in
the Supplementary Material for further details), which is given by
RS =
3
√
3σc
d1(λM − λA) −
2(d0 − r)
d1
. (9)
We demonstrate that for values of the tumor radius equal or higher than RS , the eigenvalues corre-
sponding to the radial time evolution are positive. This implies that for radii beyond RS , the tumor grows
uncontrollably evading immune responses. The nonlinear system of equations (2)-(3) was numerically
solved using the Trust-Region Dogleg method [63]. Fig. 4(A) shows the dependence of RS on the immune
recruitment rate r obtained by means of model simulations. RS represents an upper bound of the critical
tumor size that determines the long-term tumor fate, and as r increases the simulated and estimated
values get closer. For R < RS long-term or at least transient tumor dormancy can be obtained, while
R ≥ RS results in tumor escape from the immune system surveillance. In the situation of tumors with
low functional vascular levels, RS can be directly estimated by means of model simulations.
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Figure 4: Dependence of the estimated critical tumor radius RS, the tumor radius at the
unstable saddle point and control range of effector cell concentration ∆E on the immune
recruitment rate r. (A) The tumor radius at the unstable saddle point in dependence on the parameter
r derived from model simulations (blue dashed line) and compared to the approximation of RS given by
Eq. () (red solid line) for a degree of functional tumor vascularization B = 0.95. (B) ∆E with respect to
model parameters r and B. Remaining parameters are as in Tab. 1.
Control range of effector cell concentration regulates tumor evolution
The efficacy of infiltrating effector cells to control the tumor growth is derived from the properties of the
spiral point, which is always obtained for tumors with size lower than the critical threshold RS . Tumor
dormancy, and then neoplasia control, takes place when the tumor radius stays close to the spiral point
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for a long period of time. Therefore, the attraction range of the spiral point with respect to the E-axis
provides useful information about the number of effector cells required for long-term tumor control.
We claim that for arbitrary high or low initial concentrations of effector cells E0, immune-induced
tumor dormancy is not guaranteed. To illustrate the counterintuitive loss of tumor control for high or low
initial numbers of effector cells, we focus at the phase portrait diagram of Fig. 3(B). There we observe
that when the amplitude of the E(t) oscillations exceeds a certain range, the tumor escapes from the
immune system surveillance. Mathematically this is translated to the existence of a concentration range
of effector cells ∆E that is crucial for the control of tumors with size smaller than the critical radius RS .
Details of ∆E calculation are provided in the Supplementary Material.
Fig. 4(B) shows the dependence of the control range of effector cell concentration ∆E on functional
tumor-associated vasculature B and immune recruitment rate r. In particular, we observe that ∆E
increases for high enough immune recruitment rates and increasing tumor vascularization. However, at
low values of r ≤ 0.54 day−1, ∆E becomes smaller as B increases. The latter is intuitive considering that
low immune recruitment rates could not provide enough effector cells to exploit the enhanced potential
infiltration offered by increasing functional tumor vasculature. Therefore, the pro-tumoral effect of the
functional vascular network overcomes its antitumoral action.
Therapeutic potential of immuno- and vaso-modulatory interventions
Immune-mediated tumor dormancy depends not only on the effectiveness of the immune system responses,
but also on the functional tumor-associated vasculature. In consequence, we investigate the impact
of model parameters B and r, i.e. the functional tumor vasculature and immune recruitment rate,
on the overall therapeutic potential for long-term (5-years) model predictions. Therapeutic potential
TP (p) : Ωp → [0, 1] is interpreted as the average tumor control, i.e. tumor radius stays bounded, with
respect to a certain regime of model parameter p ∈ {B, r} given by
TP (p) =
∫
Ωp
H
[
RS(p)−R(p, t∗)
]
dp∫
Ωp
H
[
R(p, t∗)
]
dp
, (10)
where t∗ = 1825 days (5-years) is the target time, RS(p) is the tumor radius at the saddle point and H(·)
is a Heaviside step function. The effect of the initial tumor radius R0 and effector cell concentration E0
have been also investigated. It should be noted that a 5-years tumor-free patient is typically considered
in a complete remission stage, i.e. permanent absence of disease, and thus cured.
Any increase in the initial tumor radius R0 always reduces the therapeutic potential of the immune
system to control tumor growth, see Fig. 5. However, an optimal concentration of effector cells for
long-term tumor control is predicted irrespective of the degree of functional tumor vascularization B.
This observation implies that an arbitrary increase in the initial concentration of effector cells does not
necessarily result in a greater therapeutic benefit. It is counterintuitive that high values of E0 do not
enhance long-term tumor control. A large initial number of effector cells can induce a great initial tumor
burden reduction that makes the tumor escape immune control by an undercritical immune stimulus.
In mathematical terms, the tumor radius time evolution crosses the separatrix, escapes from the limit
cycle and enters into the unlimited growth dynamic regime (see for instance the green curve in phase
portrait diagram of Fig. 3(B), as well as the phase space and critical fixed points analysis provided in the
Supplementary Material).
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Figure 5: Therapeutic potential with respect to the initial concentration of effector cells E0
and functional tumor vascularization B for different values of the initial tumor radius R0
and immune recruitment rate r. The parameter r varies between 0.50 day−1 and 0.70 day−1 for
each value of E0 considered. The y-axis represents the ratio of 5-years tumor control situations over all
possible cases computed for the values of r and B in the ranges considered. Remaining parameters are
as in Tab. 1.
In addition to the initial concentration of effector cells, the immune recruitment dynamics play an
important role in long-term tumor control, see Fig. 6. Large values of the immune recruitment rate r
enhance the tumor control, irrespective of the tumor vascularization regime B. However, for high levels
of functional tumor vasculature, i.e. B > 0.55, large tumors with R0 > 4 mm are almost uncontrollable
at any immune recruitment rate r, see Fig. 6(C,D). We also demonstrate that the initial concentration
of effector cells required for long-term tumor control mostly depends on functional tumor vascularization
(see the phase space and critical fixed points analysis provided in the Supplementary Material).
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Figure 6: Therapeutic potential with respect to the immune recruitment rate r and functional
tumor vascularization B for different values of the initial tumor radius R0 and concentration
of effector cells E0. The parameter E0 varies between 10× 105 cells and 30× 105 cells for each value
of r considered. The y-axis represents the ratio of 5-years tumor control situations over all possible cases
computed for the values of E0 and B in the ranges considered. Remaining parameters are as in Tab. 1.
A theory-driven therapeutic proposal
Model predictions provide new insights that can be used to suggest and design novel therapeutic strate-
gies against tumor growth. The aim is to propose alternative or complementary ideas for less toxic cancer
treatments compared to conventional therapeutic modalities, such as surgery, radiotherapy or chemother-
apy. The latter cancer therapies are related to immunosuppressive effects that disallows the intention to
exploit immune system responses.
An appropriate tumor profiling via medical imaging techniques and tissue biopsy is essential. Imaging
allows for the estimation of the initial tumor size R0 and its comparison with the critical radius RS
that potentially determines the long-term tumor fate. For calculation of the precise RS value, the net
proliferation rate of tumor cells could be extrapolated from biopsy samples by following the methodology
proposed in [64]. Moreover, from the same pathology data the initial concentration of effector cells E0
can be estimated, e.g. by counting the number of CD8+ anti-tumor effector T cells. Then, the range of
effector recruitment rate could be assumed comparable to the one estimated from our experimental data,
see Tab. 1. For R0 < RS mid- or long-term controlled tumor growth is possible by clinically influencing
the interplay between immune recruitment dynamics and functional tumor-associated vasculature, as
suggested by the therapeutic potential results in Figs. 5 and 6. In the situation of R0 ≥ RS , tumor
control could not be obtained by the findings obtained from the proposed model, and complementary
treatment modalities are initially required.
Positive therapeutic responses, dR/dt < 0, can be achieved by increasing or decreasing the functional
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tumor vasculature. The latter is possible via antiangiogenic drugs, such as bevacizumab, sorafenib or
sunitinib. However, low levels of tumor vascularization trigger hypoxic-induced phenomena, and this
treatment choice typically fails after some short-term tumor burden reduction benefits [5, 6]. Hypoxic
tumor regions promote either the secretion of alternative angiogenic factors, e.g. VEGF [65], or enhanced
tumor cell migration [66], or suppressed immuno-activity allowing tumor cells to evade host immuno-
surveillance [10, 11]. Moreover, hypoxia is well known to reduce tumor cell sensitivity to radiation and
chemotherapy [67]. To avoid these adverse effects, and following our model predictions, an alternative
strategy favouring high functional tumor vasculature could be adopted, i.e. by increasing the model
parameter B. This can be realized via normalizing the tumor vasculature [2, 7, 8] or by means of a mi-
croenvironmental stress alleviation, i.e. decompression of tumor vessels, see for instance [68]. Improved
functional tumor vascularization allows for a wider range of effector cell types to infiltrate the tumor bulk
and further exterminate cancer cells [15,16]. This is supported by several preclinical studies demonstrating
that vascular normalization increases infiltration of immune effector cells into tumors and substantially
improves survival [69–71]. Indeed, vascular normalization improves tumor blood vessel perfusion, reduces
tumor hypoxia, enhances the delivery of cytotoxics and radiotherapy efficacy [11]. Counterintuitively,
normalization of tumor vasculature mitigates the metastatic risk since it is correlated to diminishing of
epithelial-mesenchymal transition of cancer cells [72].
The model predictions shown in Fig. 5 describe variations of the resulting therapeutic window of
opportunity in terms of long-term tumor control for different functional levels of tumor-associated vas-
culature B, initial number of effector cells E0 and tumor sizes R0. A negative correlation between initial
tumor sizes and mid- or long-term control is predicted. For sufficiently small tumors, optimal E0 values
range with higher therapeutic potentials exist. An increase of the immune recruitment rate results in a
higher therapeutic potential and the window of opportunity for high functional levels of tumor vasculature
still persists, see Fig. 6. Therefore, in addition to tumor vasculature normalization, applying a monitored
immunotherapy protocol could further increase the expected therapeutic benefits. Fig. 7 describes the
complete theory-driven therapeutic proposal.
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Figure 7: Theory-driven therapeutic proposal. Medical imaging and biopsy allow for estimating
the initial tumor radius R0 and concentration of effector cells E0, as well as the immune recruitment
r and tumor characteristic mitotic λM rates. If the tumor is sufficiently small, R < RS , a vasculature
normalization strategy can be implemented to substantially improve tumor control. The potential benefit
of normalizing the tumor vasculature is conducted through an increase of r and optimizing E0.
Conclusions
In this work, we have explored the possibilities offered by mathematical modeling and computer simu-
lations to gain insights into the interplay between functional tumor-associated vasculature and immune
recruitment dynamics. We have combined a radially symmetric tumor growth and an effector cell model
including the impact of vascularization on the immune system efficacy in killing tumor cells. The model
parameter calibration was based on murine experiments of in vivo tumor growth. Model analysis revealed
the existence of a tumor control window of opportunity when high functional levels of tumor vascula-
ture are present. This can be biologically perceived since high vascularization allows for the penetration
of effector cells into the tumor bulk and diminishes the adverse effects of hypoxia occurred due to low
oxygenation. Improving tumor vascularization can be mediated by a normalization of blood vessel func-
tionality [2,7,8,67,68]. Such an approach is successful only if the tumor size is below a critical threshold
that depends on tumor cell metabolic needs. Furthermore, we predict that an arbitrary increase in the
initial effector cell concentration does not necessarily imply a direct enhancement of tumor control, thus
optimal values are needed. According to our model predictions when the initial reduction of tumor size
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exceeds a specific threshold, the tumor escapes immune control and relapses faster than the associated
tumor-induced immune responses. Taking into account the dependency of tumor control on these various
mechanisms, we have proposed an alternative less toxic therapeutic approach based on a personalized
tumor profiling. This therapeutic proposal, based on normalizing the tumor vasculature, can be also
potentially combined with chemotherapy and radiotherapy to enhance the therapeutic outcomes [2,7,67].
We conclude by pointing out a number of related future research directions, as well as the limitations
of this work. The current results are based on murine experiments and therefore a parameterization on
human data would be essential. Introducing tumor vascularization dynamics should be not only a natural,
but also an insightful extension of the proposed mathematical model. Moreover, we need to further refine
the modeling of the term f(R,α) and elaborate the dependence of the exponent α on the functional tumor
vasculature B. Additionally, we could extend the notion of parameter α to reflect the dynamic feedback
of effector cell activity on local tumor density fluctuations as a time-evolving fractal dimension. At this
state, vascularization B is considered as a static parameter in time. Making tumor vasculature dynamic
would make sense to model further hypoxic effects, such as necrosis [73] or hypoxic-induced invasion [48].
Moreover, this will make possible to further investigate the dual effects of functional blood vessels on
tumor growth dynamics when cytotoxic drugs are administered as part of chemotherapy. On the other
hand, the immune system is much more complex than its description in the current model, involving a
wide range of immune cell types and intricate interactions. In particular, the immune system is often
regarded as acting to suppress tumor growth, however it is now clear that it can be both stimulatory and
inhibitory [74]. Recent advances have indicated that tumor-associated macrophages actively promote all
aspects of tumor initiation, progression and development [75]. Therefore, modeling the interplay between
macrophages and tumor cells, while taking into account the functional tumor-associated vasculature and
effector cell recruitment dynamics, may highlight new targets to develop novel anticancer strategies.
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Supplementary Material
Derivation of the mathematical model of tumor growth
We consider a non-necrotic tumor which volume growth results from a balance between cell mitosis and
death, driven by the presence of nutrients, e.g. oxygen or glucose. In the absence of inhibitor chemical
species, the spatio-temporal dynamic of the nutrient concentration σ(x, t) is modelled by the quasi-steady
reaction-diffusion equation given by
0 = D∇2σ + Γ,
where D is the diffusion coefficient and Γ is the rate at which nutrients are supplied to the tumor volume
Ω(t). The quasi-steady assumption is well supported by the observation that the diffusion time scale for
oxygen or glucose is much lower (∼ 1 minute) than the tumor cells doubling time (∼ 1 day). The rate Γ
incorporates all sources and sinks in the tumor volume, and is based on the following phenomenological
assumptions:
(1) Nutrients are homogeneously supplied by the vasculature at a rate ΓB = −λB (σ − σB), where σB is
the uniform nutrient distribution in the blood and λB is uniform.
(2) Nutrients are consumed by tumor cells at a rate λσ. This yields a rate Γ given by
Γ = −λB (σ − σB)− λσ .
The tumor is modelled as an incompressible fluid which velocity field u in Ω satisfies the continuity
equation given by
∇ · u = λP ,
where λP is the net proliferation rate of tumor cells that leads to volume growth (or shrinkage). This
formulation rests on the additional assumptions described below:
(3) The tumor is modelled as a unique homogeneously distributed phenotype, meaning that all tumor
cells behave in exactly the same manner.
(4) Tumor expansion exclusively depends on the net cell proliferation, and invasive processes, e.g. cell
migration or diffusion, are not explicitly included.
(5) The model assumes that the density of tumor cells is constant and homogeneous within the tumor bulk.
(6) The net cell proliferation rate is assumed as follows
λP = λM
σ
σ∞
− λA ,
where σ∞ is the nutrient concentration outside the tumor volume, and the mitotic λM and death rates
λA of tumor cells are uniform.
(7) The velocity is assumed to obey the Darcy’s law, i.e. porous media flow, given by
u = −µ∇P ,
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where µ is a (constant) cell motility parameter and P (x, t) is the pressure inside the tumor that is assumed
to satisfy the Laplace-Young boundary condition at the interface, which corresponds to the following as-
sumption:
(8) Cell-to-cell adhesive forces are modelled by a surface tension γ at the tumor boundary. By introducing
the intrinsic length scale LD = D
1/2/ (λB + λ)
1/2
, we obtain an intrinsic relaxation time scale λ−1R =
(µγ)−1L3D. We consider these length and time scales to non-dimensionalize the mathematical model
that can be rewritten, using bar-notation for dimensionless quantities, in terms of the modified nutrient
concentration σ¯ and pressure p¯ defined by
σ = σ∞
(
1− (1−B)(1− σ¯))
and
P =
γ
LD
(
p¯+
1
λR
(
λM (1−B)(1− σ¯) + (λA − λMB) x¯ · x¯
2d
))
,
where the parameter
B =
σB
σ∞
λB
λB + λ
represents the net effect of vascularization.
Then, by using algebraic manipulations, the original dimensional problem can be reformulated in
terms of two non-dimensional decoupled problems as follows
∇2σ¯ − σ¯ = 0,
(σ¯)Σ = 1;
and
∇2p¯ = 0,
(p¯)Σ = κ− 1
λR
(λA − λMB) (x¯ · x¯)Σ
2d
,
in a d-dimensional tumor separated from the host tissue by the interface Σ of local curvature κ that
evolves with the normal velocity v¯ = n · (u¯)Σ, and n being the outward normal to Σ.
When considering evolution of a three-dimensional tumor that remains radially symmetric, problems
above have analytical solutions that lead to the evolution equation for the dimensionless tumor radius R¯
given by
dR¯
dt¯
= v¯ =
1
λR
(
1
3
(λMB − λA)R¯+ λM (1−B)
( 1
tanh(R¯)
− 1
R¯
))
.
In particular, we have considered the dimensional version of the previous equation for the tumor
radius R = LDR¯ evolving with respect to time t = t¯/λR.
Tumor volume evolution
It is instructive to compare the proposed mathematical model of tumor growth with other modelling
approaches. In particular, we compare it with the well-known logistic growth model which has been
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extensively used in previous studies. To do that, we multiply both sides of Eq. (1) in the manuscript by
3R2, and for large radii, i.e. R LD, we obtain the following equation
3R2
dR
dt
= (λMB − λA)R3 + 3λM (1−B)LDR2,
where we have that
lim
R→∞
( 1
tanh(R/LD)
− LD
R
)
= 1.
Now, assuming that the tumor mass is M = ρV ∝ R3 and ρ is the tumor density per volume element,
then we obtain an equation for the tumor mass given by
dM
dt
= (λMB − λA)M + 3λM (1−B)LDM2/3,
where the term M2/3 denotes the mass on the surface of volume V . In particular, for B = 0, i.e. an
avascular tumor, the above equation becomes similar to the well-known von Bertallanfy equation
dM
dt
= 3λMLDM
2/3 − λAM,
which represents the growth of a body that is supplied with nutrients only from its surface. The last
equation is a kind of generalized logistic growth. In order to derive the classical logistic growth equation
we need to restrict ourselves to a two-dimensional system. As a matter of fact, the main problems with
the logistic model are:
1. It is valid only for very large tumors, but it fails to capture the dynamics of small tumors.
2. It is true only for fixed nutrient consumption within the tumor volume, i.e. no nutrient diffusion.
3. It is valid only for two-dimensional tumor evolution.
Finally under the same assumption of R  LD and for a fixed concentration of effector cells E0, we
have that
dM
dt
= (λMB − λA)M + 3λM (1−B)LDM2/3 − cE0M
2+B
3 .
The last term represents the “depth” of tumor-effector cell interactions with respect to the tumor-
associated vasculature. Obviously, for the avascular limit B = 0 such term indicated only surface inter-
actions, while for B = 1 effectors can kill cancer cells throughout the tumor bulk.
Model non-dimensionalization
The process of non-dimensionalization allows for (i) scaling the system of variables according to their
characteristic quantities, (ii) writing the system by reducing as much as possible the number of model
parameters, and (iii) identifying their appropriate units. To do that, we assume as reference length size
the model parameter LD, and the initial number of effector cells as reference concentration Eref , for the
variables R and E respectively. The diffusion length LD ranges in the interval [0.2 mm, 0.3 mm] [58,59,76],
and the effector cell characteristic concentration Eref is at the order of magnitude 10
5 cells. The latter
estimate is justified since the characteristic length scale of the system is at the order of 1 mm, and given
that cells are commonly assumed with a diameter between 10 µm and 20 µm [57], then for a volume of
1 mm3 the concentration is at the order of magnitude 105 cells. Moreover, the time scale is proportional
to tumor cell deactivation, i.e. t′ = (c′Eref )t, where the parameter c′ is provided below.
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Thus, the non-dimensional system of ordinary differential equations for the new variables R′ = R/LD
and E′ = E/Eref is given by
dR′
dt′
=
1
3
(λ′MB − λ′A)R′ + λ′M (1−B)
(
1
tanh(R′)
− 1
R′
)
− c′E′ R
′B
R′(B−1) + L(1−B)D
,
dE′
dt′
= r′
R′3
K ′ +R′3
E′ −
(
d′1
R′3
R′(1−B) + L(B−1)D
+ d′0
)
E′ + σ′,
where the non-dimensional model parameters are summarized as follows
c′ = c, λ′M =
λM
c′Eref
, λ′A =
λA
c′Eref
,
r′ = rc′Eref , K
′ = K
L3D
, d′1 =
d1L
(2+B)
D
c′Eref
, d′0 =
d0
c′Eref
, σ′ = σ
c′E2ref
.
It should be noted that the inactivation rate of effectors by encounters with tumor cells interestingly
depends on the parameter B, i.e. the functional tumor vasculature, by means of the dimensionless
parameter d′1.
Phase space and critical fixed points
The nullclines, i.e. zero-growth isoclines, as well as critical fixed points corresponding to different model
parameter values of the tumor-effector cell recruitment dynamical system (R-E axis), are shown in Fig. 8.
The intersections of the nullclines, i.e. the curves along which dR/dt = 0 and dE/dt = 0, represent the
critical fixed points of the system. Fig. 8 shows that a spiral and a saddle point are present, which are
represented by S and U on each phase diagram respectively. At the spiral point the time evolution of R
oscillates around a small tumor size, and the separatrix defines sharp boundary between tumor growth
and shrinkage depending on the initial conditions, see also Fig. 3 in the manuscript. There exists a critical
tumor size that coincides with the saddle point and above which tumors always grow uncontrollably and
the immune system is completely suppressed. Below this threshold, tumors are always controlled when
the spiral point is stable, or at least for some period of time if it is unstable, provided the immune
responses are in a specific range. Therefore, the mathematical model is capable of explaining both tumor
dormancy and escape from immunosurveillance.
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Figure 8: Nullclines and critical fixed points. The nullclines dE/dt = 0 (blue lines) and dR/dt = 0
(red lines) are plotted for different values of model parameters r and B, i.e. immune recruitment rate
and functional tumor-associated vasculature respectively. The intersections of the nullclines represent
the spiral and saddle points of the system, denoted by S and U respectively. Remaining parameters are
as in Tab. 1 of the manuscript.
A quick glance at Fig. 8 reveals that the distance between the critical fixed points depends on the model
parameter values. Fig. 9 represents the position of the critical fixed points on the R-E axis for different
values of functional tumor vascularization B and immune recruitment rate r. The variations of the tumor
radius corresponding to the spiral point are always smaller, ranging between 1.59 mm to 2.08 mm, than
for the unstable saddle point, varying from 2.82 mm to 5.80 mm, see Fig. 9(A,B) respectively. For B → 1
and small values of r, the spiral and saddle points approach each other in the R-axis. Accordingly, this
means that as the immune recruitment rate decreases and functional tumor vascularization increases, the
tumor becomes less controllable, i.e. the region for favorable initial conditions in terms of long-term tumor
control is lower. Conversely, at high immune recruitment rates and low tumor vascular functionality, the
tumor can be controlled in a range of initial conditions, which is consistent with expectations. The initial
concentration of effector cells E only weakly depends on the immune recruitment rate r, but mostly on
the level of functional tumor vascularization B, see Fig. 9(C,D). Concentrations of effector cells associated
with the spiral and the saddle points both increase with increasing tumor vasculature, and approximately
to the same extent, which corresponds to a parallel shift on the E-axis of both critical fixed points, see
Fig. 9(C,D).
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Figure 9: Position of the critical fixed points in the phase space. Position dependence of the
spiral and saddle points on different values of model parameters r and B, i.e. immune recruitment rate
and functional tumor-associated vasculature respectively. (A,B) Tumor radius and (C,D) effector cell
concentration corresponding to the spiral (A,C) and saddle points (B,D). Remaining parameters are as
in Tab. 1 of the manuscript.
Bifurcation analysis
In order to explore the critical parameter values at which the qualitative long-term dynamics of tumor
evolution changes, we generated one-parameter bifurcation diagrams for the functional tumor vasculature
B and immune recruitment r, with the tumor radius plotted as a function of such parameters. Stable
and unstable solution branches are represented by solid and dashed lines respectively. The Hopf and
limit bifurcation points are indicated by H and LP respectively. A Hopf point is a local bifurcation
in which a fixed point of a dynamic system loses stability as a pair of complex conjugate eigenvalues
of the linearization around the fixed point cross the imaginary axis of the complex plane, i.e. when the
eigenvalues are a complex conjugate pair whose real part changes sign. The bifurcation analysis has been
conducted by a prediction-correction continuation algorithm using the software MATCONT [77].
For functional levels of the tumor-associated vasculature in a range around B = 0.75 and bound by the
Hopf bifurcation points H1 and H2, the spiral fixed point is a repellor, see Fig. 10. Consequently, for B in
this range and for the different values of r, uncontrolled tumor growth occurs. Out of this critical range,
i.e. for lower and higher values of B, the spiral fixed point is an attractor, where long-term tumor control
is reached. Not only low levels of functional vasculature allows for long-term tumor control, but there
exists a therapeutic window of opportunity for well-vascularized tumors, see Fig. 10. With increasing
immune recruitment rate r, the distance between the Hopf bifurcation points decreases, implying that
the observed window of opportunity increases, while at the same time the global region of unfavourable
situations decreases.
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Figure 10: Bifurcation diagrams with respect to the functional tumor-associated vascu-
lature B. One-parameter bifurcation diagrams for different values of the immune recruitment rate
r = {0.54, 0.57, 0.60, 0.64} day−1 in reading order. The labels H1 and H2 represent Hopf bifurcation
points, while the solid and dashed lines describe the stable and unstable solution branches respectively.
The concentration of effector cells E corresponding to H1 and H2 are also provided. Remaining param-
eters are as in Tab. 1 of the manuscript.
In the case of one-parameter bifurcation diagrams with respect to the immune recruitment rate r,
see Fig. 11, we observe a limit and a Hopf bifurcation point. When tumor vascular functionality B
increases, the stable branch is gradually reduced and the Hopf bifurcation point moves from low to high
values of r. However, there exists a value of B, at which this behaviour is inverted and the stable branch
gets larger again. The range of r values associated with the stable branch for B = 0.95 is similar to
the one obtained for low values of B, for instance B = 0.40, see Fig. 11. In other words, even for a
tumor with a highly functional vascular network, long-term control can be achieved for a wide range of
immune recruitment rates. This finding suggests an alternative therapeutic strategy to the conventional
antiangiogenic treatments.
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Figure 11: Bifurcation diagrams with respect to the immune recruitment rate r. One-
parameter bifurcation diagrams for different values of functional tumor-associated vasculature B =
{0.40, 0.60, 0.80, 0.95} in reading order. The labels H and LP represent a Hopf and a limit bifur-
cation point respectively. The solid and dashed lines describe the stable and unstable solution branches
respectively. The concentration of effector cells E corresponding to H and LP are also provided. Re-
maining parameters are as in Tab. 1 of the manuscript.
Estimation of the critical radius for tumor dormancy
We derive an analytical expression that approximates the R-E axis position of the saddle point, which
corresponds to an upper bound estimation. R LD and B → 1 imply in Eq. (2) in the manuscript that
LD
R → 0 and tanh (R/LD)→ 1, as well as that R
B
R(B−1)+1 → R2 . These simplifications and the quasi-steady
state approximation of Eq. (2) yields
1
3
(λM − λA)R− cER
2
= 0,
which implies that
E =
2(λM − λA)
3c
.
Arguing similarly for Eq. (3) in the manuscript and under the same assumptions, we have that
R3
K+R3 → 1 and R
3
1+R(1−B) → R
3
2 , where
rE −
(
d1
R3
2
+ d0
)
E + σ = 0,
and then we obtain that
E = − σ
r − (d1R32 + d0) .
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Combination of the previous equations for E results in an approximation of the value of R corre-
sponding to the critical tumor radius, R-axis position of the saddle point, given by
RS =
3
√
3σc
d1(λM − λA) −
2(d0 − r)
d1
.
Estimation of control range of effector cell concentration
We define the control range of effector cell concentration ∆E as the maximum difference of the E-axis
spiral point position and the number of effectors E∗ given by the separatrix that defines sharp boundary
between tumor dormant states and uncontrollable growth. Combinations of estimated ∆E with the
position of the critical fixed points in the phase space for a given set of model parameters provide
information about the ability of the immune responses to induce long-term tumor control. Values of
initial concentration of effector cells E0 out of ∆E will not result in long-term tumor dormancy, which
suggests limitations of therapeutic immuno-modulatory interventions.
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